Ninel Hovnanians, MD, is a general cardiologist and medical director of the Cardiac Fitness Center at UWMC Northwest.

 on July 16, 2026, to lower LDL-C in adults with 

, became available for prescription in August; however, the drug’s lack of a cardiovascular indication limits its use beyond an addition to statins.

The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD

Enlicitide is the first oral PCSK9 inhibitor to receive FDA approval – historically, they have only been available as injectables administered once or twice a month. A leading draw for enlicitide is the avoidance of treatment adherence issues raised by regular injections. Currently, however, it is only cleared as an add-on to statin therapy following evidence that statins alone are not sufficiently reducing LDL-C to the clinical target level.

“A lot of my patients were calling and asking whether they could just switch to enlicitide now that it’s been approved, but none of the studies have actually been done on their own, and all of them have been in addition to moderate or high intensity or the highest tolerable dose of statins,” Ninel Hovnanians, MD, general cardiologist and medical director of the Cardiac Fitness Center at UWMC Northwest, told 

 in an exclusive interview. “We don’t have any comparison to say whether these medications really have the same benefits on their own.

The FDA’s approval was based on the CORALreef Lipids trial, a multinational, double-blind, randomized, placebo-controlled trial evaluating patients with a history of a major atherosclerotic cardiovascular disease (ASCVD) event who had an LDL-C of ≥55 mg/dL, as well as patients at risk for a first ASCVD event with an LDL-C of ≥70 mg/dL. Patients were assigned in a 2:1 ratio to either enlicitide 20 mg or placebo daily for 52 weeks.

The primary endpoint of CORALreef Lipids was mean percent change in LDL-C from baseline to week 24. Secondary endpoints included the mean percent change in LDL-C at week 52 and in non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) at week 24.

Of the 2909 patients enrolled in the trial, 1935 received enlicitide and 969 received placebo, while 5 did not receive either. Mean age was 63 years, and 39.3% of enrolled patients were women. Mean LDL-C (+/- standard deviation [SD]) at baseline was 96.1 +/- 38.9 mg/dL. By week 24, mean percent change was -57.1% (95% CI, -61.8 to -52.5%) with enlicitide and 3% (95% CI, 0.9 to 5.1) with placebo, with a between-group difference of -55.8% (95% CI, -60.9 to -50.7%; 

 <.001). Additionally, mean percent changes in all secondary endpoints were significantly greater with enlicitide than with placebo.

Despite these positive data, neither the CORALreef Lipids trial nor the accompanying CORALreef HeFH trial was powered to determine its effects on cardiovascular outcomes directly. The current FDA approval only clears it for use alongside statins to reduce lipid levels; further investigation is needed before it can be evaluated as a cardioprotective medication in isolation.

However, an ongoing trial from Merck, the phase 3 CORALreef Outcomes study, is currently evaluating enlicitide’s capacity to increase time to first occurrence of major adverse cardiovascular events compared to placebo. With an expected completion date of November 2029, this program aims to bridge the aforementioned gap in indication and allow clinicians to prescribe enlicitide for cardiovascular benefit as well.

“The most important thing to remember is that this is an add-on therapy to statins and not a standalone medication,” Hovnanians said. “I think that this is the question that’s brought up to me by my patients the most.”

Editors’ Note: Hovnanians reports no relevant disclosures.

Donohue B. Statins not enough? New pill expected to lower cholesterol. 

. August 26, 2026. Accessed October 5, 2026. 

https://newsroom.uw.edu/blog/statins-not-enough-new-pill-expected-to-lower-cholesterol/

Merck. Merck’s LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia. July 16, 2026. Accessed October 5, 2026. 

https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/

Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. New England Journal of Medicine. 2026;394(6):529-539. 

Merck Sharp & Dohme. Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes. ClinicalTrials.gov Identifier: NCT06008756. Updated April 23, 2026. Accessed October 5, 2026. 

https://clinicaltrials.gov/study/NCT06008756

Videos

Hovnanians discusses the benefits of oral versus injectable PCSK9s, as well as the ongoing research to clear enlicitide alone for cardiovascular indications.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 and nephrotic syndrome, final phase 3 data in 

, and expert perspective on kidney disease detection and glomerular disease care.

The FDA approved finerenone (Kerendia) to reduce albuminuria in adults with CKD associated with 

. Later in the month, obinutuzumab (Gazyva) was approved for relapse prevention in patients with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome, adding to its existing indication in lupus nephritis.

In IgAN, final results from the phase 3 ORIGIN 3 trial showed that atacicept (Trutakna), which inhibits B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), preserved kidney function through 2 years. The data support a planned application for full approval, following the drug's accelerated approval in July 2026.

Coverage also focused on detection and coordination of care. As the US Preventive Services Task Force (USPSTF) reviews evidence on CKD screening, the American Kidney Fund highlighted how often the disease goes undiagnosed, and a new American Society of Nephrology (ASN) resource aims to consolidate guidance on glomerular disease.

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

On September 16, 2026, the FDA approved finerenone (Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with CKD associated with type 1 diabetes. The approval was based on the phase 3 FINE-ONE trial, in which finerenone reduced UACR by 28% compared with placebo at month 6. Hyperkalemia occurred in 10.1% of patients receiving finerenone and 3.3% receiving placebo. Bayer described it as the first new treatment option for this population in more than 30 years.

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

On September 25, 2026, the FDA approved obinutuzumab (Gazyva) for relapse prevention in patients aged 2 years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in complete remission. In the phase 3 INShore trial, 95.5% of patients receiving obinutuzumab maintained complete remission at week 52, compared with 73.2% receiving mycophenolate mofetil. Genentech's obinutuzumab was approved for lupus nephritis in 2025.

Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data

Final phase 3 ORIGIN 3 data from Vera Therapeutics showed that atacicept (Trutakna) reduced the risk of kidney disease progression by 76% compared with placebo in 428 patients with IgAN. Annualized estimated glomerular filtration rate (eGFR) decline through 104 weeks was 0.6 mL/min/1.73 m² per year with atacicept and 5.6 with placebo. No patients receiving atacicept required dialysis or transplant or died, compared with 8 events with placebo. Vera plans to submit a supplemental application for full approval in the fourth quarter of 2026.

Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna Norouzi, MD

Sayna Norouzi, MD, of Loma Linda University Medical Center, discusses the ORIGIN 3 final analysis, in which atacicept slowed eGFR decline to a rate close to normal age-related loss. She covers why preserving kidney function is the outcome patients ask about most, how the results relate to KDIGO treatment targets, and the trial's safety findings, including similar infection rates with atacicept and placebo.

Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella

Pranav Garimella, MBBS, MPH, chief medical officer of the American Kidney Fund, discusses why 87% of US adults with CKD are unaware of their diagnosis and what the USPSTF should consider in its evidence review on CKD screening. He covers the gap between eGFR and UACR testing in patients with type 2 diabetes, high-risk groups for screening, the need for repeat testing to confirm CKD, and newer therapies such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, finerenone, and glucagon-like peptide-1 (GLP-1) receptor agonists.

New ASN Compendium Tackles Fragmented GN Care, With Vasquez-Rios, MD

George Vasquez-Rios, MD, MSCR, of Renal Medicine Associates, discusses the ASN Glomerular Diseases Collaborative (GD-C) Compendium, which consolidates guidance on glomerular diseases including IgAN, lupus nephritis, ANCA-associated vasculitis, 

, and membranous nephropathy. He explains how the compendium serves both general nephrologists and specialists, includes a recognition-to-referral pathway and guidance on prior authorizations, and is updated about every 6 months.

Articles

September 2026 saw major nephrology milestones spanning CKD, nephrotic syndrome, and IgA nephropathy, alongside heightened attention to detection and care coordination. Finerenone gained an FDA indication to lower albuminuria in type 1 diabetes–associated CKD, with hyperkalemia as a key safety signal. Obinutuzumab was approved to prevent relapse in frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome. In IgAN, atacicept demonstrated sustained eGFR preservation and a marked reduction in progression risk through 104 weeks, supporting a planned full-approval submission.

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

6 Nephrology Headlines You Missed in September 2026

, from phase 2 data for a new interleukin-23 (IL-23) inhibitor in 

 to the role of gut fungi in disease activity, along with new research in chronic pancreatitis and 

In ulcerative colitis, Spyre Therapeutics reported that SPY003, an extended half-life IL-23 antibody, met the primary endpoint of the open-label portion of the phase 2 SKYLINE-UC trial, with a placebo-controlled portion now underway. A separate study in 

 examined whether treating fungal overgrowth with an antifungal could affect IBD activity.

IBD coverage also looked at how treatment success is defined. The comprehensive disease control framework sets a goal that extends beyond symptom relief and bowel inflammation to include patients' overall function and quality of life.

Outside IBD, a meta-analysis estimated that 

 affects 40% of patients with chronic pancreatitis, with estimates varying by diagnostic test and region. Researchers at Vanderbilt University Medical Center also identified a gene module that helps 

 resist the antibiotic bacitracin, a potential target for adjunctive therapy.

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis


On September 8, 2026, Spyre Therapeutics announced that SPY003 met the primary endpoint in Part A of the phase 2 SKYLINE-UC platform trial. Among 44 patients receiving open-label monotherapy, Robarts Histopathology Index scores showed a 10.0-point reduction from baseline at week 12. Clinical remission occurred in 20% of patients and endoscopic improvement in 30%. Topline data from Part B, which includes combination arms, are expected in 2027.

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD

Iliyan D. Iliev, PhD, of Weill Cornell Medicine, discusses his study of 53 patients with IBD and oral thrush, in which fluconazole, but not nystatin rinse, was associated with improved disease activity in both ulcerative colitis and Crohn disease over 8 weeks. He covers the line between commensal fungi and fungal overgrowth, the need for placebo-controlled trials, and why short-term, targeted antifungal therapy may be more practical than long-term use.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD

David T. Rubin, MD, director of the IBD Center at the University of Chicago, explains comprehensive disease control, a treatment target that combines symptomatic remission, normalized markers of inflammation, and functional remission. He discusses why patients who feel well may still have active inflammation and how extraintestinal factors such as joint pain, depression, and sexual health fit into IBD care.

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

 of 14 studies including 7,663 patients with chronic pancreatitis estimated a pooled EPI prevalence of 40.0%. Prevalence ranged from 52.1% with fecal elastase-1 testing to 21.1% with fecal fat testing, and smoking was associated with 51% higher odds of EPI. The authors called for standardized diagnostic protocols.

C Diff Resistance to Bacitracin Reveals Potential Drug Target

 uses a 6-component gene module to resist bacitracin, an antibiotic produced by commensal gut bacteria, while adapting to iron-limited conditions in the host. In mice infected with strains lacking key module genes, bacitracin reduced bacterial burden to undetectable levels and all mice survived. The findings suggest that blocking the module could restore bacitracin sensitivity.

September 2026 gastroenterology updates emphasized IBD therapeutics and pathobiology alongside advances in pancreatology and C difficile. An extended half-life IL-23 antibody in ulcerative colitis showed histologic improvement with early remission and endoscopic response signals, with combination data pending. Emerging translational work linked fungal overgrowth to IBD activity, suggesting selective systemic antifungals may modulate disease. Clinical targets are evolving toward comprehensive disease control incorporating functional remission and extraintestinal impacts. Additional research highlighted high EPI prevalence in chronic pancreatitis and identified a bacitracin-resistance module as a potential C difficile adjunctive target.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

C Difficile Infection

C. difficile condition center page, resources on the topics of medical news and expert insight into Clostridium difficile can be found. Content includes articles, interviews, videos, podcasts, and breaking news on C. diff research, treatment, and drug development.

5 Gastroenterology Headlines You Missed in September 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.


NAV-240 and NAV-242 are investigational bispecific antibodies from Navigator Medicines targeting both TNFα and OX40L. NAV-242 is a subcutaneous, half-life-extended version designed for less frequent dosing.

What did the late-breaking HS spatial mapping study show?


Research led by Johannes Griss of the Medical University of Vienna found TNFα and OX40L concentrated near tunnel-associated cells in HS skin, suggesting both pathways contribute to inflammation in draining tunnels.

Tumor necrosis factor alpha (TNFα) and OX40 ligand (OX40L) both cluster near cells surrounding draining tunnels in 

 skin, according to late-breaking spatial mapping data presented at the 

2026 European Academy of Dermatology and Venereology (EADV) Congress

 in Vienna, Austria. Navigator Medicines, which supported the research, is developing 2 bispecific antibodies designed to block both targets simultaneously.¹

The company also presented early-phase safety data for its lead candidate, NAV-240, and preclinical findings for a longer-acting successor, NAV-242. A phase 2a trial of NAV-240 in HS is enrolling faster than anticipated, according to Navigator.¹

Johannes Griss, MD, PhD, an associate professor at the Medical University of Vienna, led the analysis of skin sections from patients with HS. Both TNFα and OX40L localized close to tunnel-associated cells, implicating the 2 pathways in disease pathology.¹

Griss presented the findings in a late-breaking session on October 1, 2026 (D2T01.4B). In the company's announcement, he said pinpointing where the immune response occurs in HS is essential for designing better therapies. He interpreted the concentration of both molecules at tunnel sites as evidence they work in concert to maintain inflammation, supporting continued investigation of dual-targeting agents.¹

Navigator suggested bispecific antibodies acting on both pathways could reduce inflammation specifically where tunnels form. Draining tunnels, also called sinus tracts or fistulas, develop beneath the skin in more advanced disease and contribute to pain, scarring, and daily burden.¹

What Did Early Data Show for NAV-240 and NAV-242?

A poster (P1749) reported translational data from phase 1 single and multiple ascending dose studies of NAV-240 in 64 healthy volunteers. According to the company, the agent showed acceptable safety and tolerability, low immunogenicity, and pharmacodynamic results consistent with its dual mechanism. Antiviral T-cell function was preserved, which Navigator described as important for long-term immune health.¹

A second poster (P1782) presented preclinical data showing NAV-242 had greater stability and longer in vivo pharmacokinetics than NAV-240. Early cohorts of an ongoing phase 1a/b study of subcutaneous NAV-242 in healthy participants have confirmed an extended half-life, the company reported. The analysis is evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity, with full results expected in the second half of 2027.¹

Tosh Butt, chief executive officer of Navigator Medicines, said the extended half-life of NAV-242 gives it potential for a differentiated dosing schedule.¹

The phase 2a MAINSAIL trial (NCT07384975) is a multicenter, randomized, double-blind, placebo-controlled study of NAV-240 in adults with moderate to severe HS. Investigators will assess changes in abscesses, nodules, and draining tunnels, along with quality of life outcomes.¹˒²

Navigator expects MAINSAIL results in the third quarter of 2027 and plans to use them to guide development of both NAV-240 and NAV-242.¹

Neither agent has been approved by any regulatory authority. The release did not provide numerical safety, pharmacokinetic, or half-life data, and the spatial mapping study did not report the number of patients or samples analyzed.

Editor’s note: This summary has been edited for grammar and clarity using artificial intelligence tools.

Navigator Medicines presents new data at EADV 2026 as bispecific antibody program advances at speed in hidradenitis suppurativa. News release. Navigator Medicines. September 29, 2026. Accessed October 5, 2026. 

https://www.navigatormedicines.com/pr_september-29-2026

MAINSAIL: NAV-240 in moderate to severe hidradenitis suppurativa. ClinicalTrials.gov identifier: NCT07384975. Accessed October 5, 2026. 

https://clinicaltrials.gov/study/NCT07384975

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 regulatory and pipeline activity from July through September 2026 centered on new mechanisms and psychedelic therapies. The 

 approved centanafadine (Simtriyo), the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for ADHD. Resilient Pharmaceuticals resubmitted its MDMA-assisted therapy new drug application (NDA) for PTSD, and Definium Therapeutics' DT120 received a second Breakthrough Therapy designation in 

Phase 3 data advanced the psychedelic pipeline, including 26-week COMP006 results for COMP360 psilocybin in treatment-resistant depression (TRD) and positive Voyage results for DT120 in generalized anxiety disorder (GAD). A September FDA public hearing also raised the question of whether the clinical workforce is ready for its first psychedelic approval.

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years

On July 24, 2026, the FDA approved once-daily extended-release centanafadine for ADHD in adults and in pediatric patients aged ≥ 6 years who weigh ≥ 20 kg. The approval was based on 4 randomized, placebo-controlled phase 3 trials. In the pediatric trials, improvement on the ADHD Rating Scale-5 appeared by week 1 and lasted through week 6.

The label has boxed warnings for suicidal ideation and behaviors in children aged 6 to 12 years and for abuse, misuse, and addiction. Commercial availability depends on scheduling by the Drug Enforcement Administration (DEA).

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD

Resilient Pharmaceuticals, formerly Lykos Therapeutics, resubmitted its NDA for MDMA-assisted therapy in PTSD without running a new phase 3 trial. The Multidisciplinary Association for Psychedelic Studies (MAPS) confirmed the resubmission on August 10, 2026. The FDA's August 2024 complete response letter (CRL) had asked for more data on durability of response, safety characterization, and bias mitigation.

In July 2026, the FDA issued final guidance on clinical investigations of psychedelic drugs, which covers those same areas.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD

On September 8, 2026, the FDA granted DT120 (lysergide) orally disintegrating tablet (ODT) Breakthrough Therapy designation for MDD. The drug already held the designation for GAD. Definium has not disclosed a submission timeline for either indication.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial

Voyage randomized 214 adults with GAD to a single 100 µg dose of DT120 ODT or placebo. At week 12, scores on the Hamilton Anxiety Rating Scale (HAM-A) fell 5.4 points more with DT120 than with placebo (

 = 0.81). Response rates were 43% vs 16%, and remission rates were 14% vs 4%.

What New 26-Week COMP006 Data Mean for TRD, With Boadie Dunlop, MD

In COMP006, 39% of participants given COMP360 25 mg had a MADRS reduction of ≥ 25% by week 6, and that response was maintained on average through week 26. Among week 6 responders who had not yet remitted, nearly 30% reached remission after a second dose. Boadie Dunlop, MD, MSC, of the Medical College of Georgia at Augusta University, said serious adverse event rates were similar in the 1 mg and 25 mg arms (6.3% vs 5.7%).

Compass Pathways plans to submit an NDA in the fourth quarter of 2026.

COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks

COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

At Psych Congress 2026, Helus Pharma presented the design of PARADIGM, a phase 3 program for HLP003, a deuterated psilocin analog. Patients with MDD and an inadequate response to antidepressants receive 2 doses given 21 days apart as add-on treatment. The program includes APPROACH (n = 223; enrollment complete), EMBRACE (n = ~ 330), and a 43-week extension, with change in MADRS at day 42 as the primary endpoint.

APPROACH topline data are expected in the fourth quarter of 2026. Helus is targeting a possible NDA in 2028.

Psychiatry activity in Q3 2026 emphasized first-in-class reuptake inhibition and late-stage psychedelics. Centanafadine, an NDSRI, gained FDA approval for ADHD in adults and children ≥6 years, with rapid symptom improvement but boxed warnings for suicidality and abuse potential pending DEA scheduling. An MDMA-assisted therapy NDA for PTSD was resubmitted amid new FDA psychedelic-trial guidance focused on durability, safety, and bias. DT120 (lysergide) expanded Breakthrough Therapy designations and showed clinically meaningful phase 3 efficacy in GAD, while COMP360 psilocybin demonstrated sustained TRD benefit through 26 weeks.

Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

PTSD

Q3 2026 Recap: Psychiatry News and Updates

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

Aaron Waxman, MD, PhD, is the executive director of the Center for Pulmonary Heart Diseases at Brigham and Women’s Hospital.

Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

FDA News

FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data

Iltefat H. Hamzavi, MD, explains why vitiligo responds slowly, why stabilization matters, and what Tranquillo data mean for future treatment.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD

Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.

Hepatology

5 Hepatology Headlines You Missed in September 2026

Adherence starts with finding a treatment patients can realistically sustain. The expert faculty discuss how shared decision-making and patient education can help translate an EoE treatment plan into long-term action.

Video Series

Strategies to Improve Treatment Adherence in EoE Care

Effective EoE management requires more than controlling disease activity. The panel explores how evolving clinical needs and quality-of-life considerations can guide treatment decisions over time.

Adjusting Treatment and Quality of Life in EoE

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Advances in Treating High-Impact Psoriasis from EADV 2026

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

8 Endocrinology Headlines You Missed in Q3 2026

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

Latest News

The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD

6 Nephrology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Q3 2026 Recap: Psychiatry News and Updates